Drug Status Report

**Drug**: 5-(1,1-Dimethyloctyl)-2-(3-hydroxy-5,5'-dimethylcyclohexyl)phenol

**Drug Name Status**: 5-(1,1-Dimethyloctyl)-2-(3-hydroxy-5,5'-dimethylcyclohexyl)phenol is the chemical name.

**Chemical Name**: 5-(1,1-Dimethyloctyl)-2-(3-hydroxy-5,5'-dimethylcyclohexyl)phenol

**Chemical structure**: 

![Chemical structure diagram](image)

**Molecular Formula**: C_{24}H_{40}O_{2}

**Pharmacological class / Application**: cannabinoid

**International status**:

US: The substance is not currently listed on the schedules to the US Controlled Substances Act and is not mentioned on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: 5-(1,1-Dimethyloctyl)-2-(3-hydroxy-5,5'-dimethylcyclohexyl)phenol is believed to be a novel analogue of 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol, which is more commonly known as the C8 homologue of CP-47,497. CP-47,497 is a potent cannabinoid receptor agonist and studies have shown that the addition of alkyl groups to the cyclohexanol ring of CP-47,497 at the C-4 position does not affect the efficacious agonist activity of the substance\(^1\). However, there are no reports in the scientific literature regarding the *in vivo* activity of CP-47,497 C8 homologue substituted with alkyl groups at the C-5 position in the cyclohexanol ring.

Cannabinoid receptor agonists have been declared to be included within item 1 of Schedule II to

the CDSA by virtue of being “similar synthetic preparations” while cannabinoid receptor antagonists have been declared to fall outside item 1 of Schedule II to the CDSA. Although 5-(1,1-Dimethyloctyl)-2-(3-hydroxy-5,5'-dimethylcyclohexyl)phenol displays significant structural similarity to the C8 homologue of CP47,497, there are no reports in the scientific literature that the substance is an efficacious cannabinoid receptor agonist. Accordingly, the substance cannot be in item 1 of Schedule II to the CDSA.

It is noteworthy that a similar decision was made on the synthetic cannabinoid JWH-250 which was not included under item 1 of Schedule II to the CDSA on the basis that there is no evidence in the scientific literature to confirm that JWH-250 behaves as an efficacious cannabinoid receptor agonist.

Recommendation: 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol is not included in item 1 of Schedule II to the CDSA and is not a controlled substance.

29th June, 2010